I N T R O D U C T I O N
Potent immunosuppressive agents have transformed the outcome in anti-neutrophil cytoplasm antibody (ANCA)-associated vasculitis (AAV) with over 70% of patients surviving at least 5 years from initial therapy [1] . However, there is a 38% risk of relapse [2] , a high risk of infection and other side effects [3] , chronic effects of scarring such as renal impairment or cardiovascular events [4] and an increased risk of malignancy [5] . High doses of glucocorticoid therapy induce comorbidity and exacerbate existing comorbidity such as diabetes, heart failure, hypertension and risk of fracture [6] .
In other words, the AAVs are really a form of chronic relapsing inflammatory disease and as such they require careful monitoring to ensure that the appropriate management is given at each stage of the disease. Although the initial presentation is primarily due to active vasculitis, there is a constant need to look for and manage coexisting medical problems such as infection, organ failure or diabetes. Patients usually respond well to their induction treatment [7] . We should not automatically assume that any subsequent deterioration is due to active vasculitis; we should avoid increasing immunosuppression without justification. Many patients achieve successful induction of remission of their vasculitis as a result of glucocorticoid and cyclophosphamide (or rituximab) therapy, but subsequently develop what might be flare (e.g. blood stained nasal discharge, or cough and pulmonary infiltrate). Further assessment is necessary to determine whether they have sepsis or a relapse, or both, or other comorbid events.
Unfortunately, the serological tests ( plus positive histology) that are useful for diagnosis, such as ANCA titres, are not necessarily valuable (or feasible) in follow-up [8] , where 40% of patients with a rise in ANCA titre do not suffer a new clinical event. C-reactive protein (CRP) and erythrocyte sedimentation rate are affected by disease activity but also by infection; highly sensitive CRP may be of value in predicting future relapse [9] . Renal impairment may be due to active vasculitis or chronic scaring damage or secondary effects of hypertension.
Regular use of validated disease activity and damage measurements as part of routine care offers a structured approach which can serve as the basis of justifying treatment decisions. However, assessment is dependent on the expertise of the observer. The assessment allows the clinician to document those manifestations that reflect the disease activity as well as those reflecting damage and chronicity. Because of the complex nature of vasculitis, the assessments cannot be entirely comprehensive, covering every eventuality. However, they can form the core of the clinical assessment of the patient, acting as a useful component of the management of patients with vasculitis. If they are seen as an additional chore, then they will be a burden and of less value to the clinician. Figure 1 shows the different aspects of disease evaluation that are routinely considered in clinical trials of vasculitis and these aspects are being increasingly introduced into clinical practice. There are a wider number of tools being developed in each of the three areas of disease activity assessment, disease damage assessment and functional assessment. Figure 2 suggests the role that disease assessment tools can play in the routine care of patients with systemic vasculitis.
Eligibility for inclusion in clinical studies of vasculitis is increasingly defined by the level of disease activity measured using one of the scores; the definition of flare, remission and response is couched in terms of changes in the score [10] . The Outcome Measures in Rheumatology Clinical Trials (OMERACT) group has approved the Birmingham Vasculitis Activity Score (BVAS) and its variants [7, 11, 12] and the Vasculitis Damage Index (VDI) [13] for use in clinical trials and studies [14] . The rigour of OMERACT methodology is supported by the Food and Drugs Administration (FDA). Assessments approved by the OMERACT group can be used as part of the licensing process for new or existing drugs. Vasculitis is a complex set of conditions and therefore the tools to evaluate it are necessarily complex. It is strongly recommended that training is undertaken prior to using these tools in clinical practice or in studies; it is increasingly mandated for industry-led and academic-led research in vasculitis. Online training is available for these tools [15] .
AC T I V I T Y A N D D A M A G E A S S E S S M E N T

Measurement of disease activity in vasculitis
The multi-system nature of vasculitis means that any clinical assessment is going to require evaluation in each body system. Several different instruments have been developed over the last two decades. The Groningen Index [16] requires histological evaluation of activity and is therefore not practical for serial assessment. The Vasculitis Activity Index (VAI) [17] relies on visual analogue measures of disease activity; it is simple to complete but has poor inter-observer reliability [11] . The BVAS [7, 11] has been the most successful of these instruments and is widely used in clinical trials, as well as being recommended for clinical practice (http://www.england.nhs.uk/wp-content/ uploads/2013/04/a13-p-a.pdf).
In the NHS England policy document on management of ANCA-associated vasculitis with rituximab it is recommended that disease activity is measured using BVAS prior to and following treatment in order to demonstrate significant benefit from the drug. It is likely that such tools will be mandated in the future as a result of development of more complex, and also more expensive therapies. It is important to demonstrate that the treatment is effective in order to justify the cost. The BVAS is a checklist of features that typically occur in patients with F I G U R E 1 : Clinical tools available to assess disease activity, damage and function in systemic vasculitis (Note that the term BVAS/GPA describes one of the assessment tools designed prior to the change of disease name from 'Wegener's granulomatosis' to 'granulomatosis with polyangiitis'. Some earlier articles refer to this as BVAS/WG.). active systemic vasculitis. It was designed to evaluate patients with many different forms of vasculitis. However, it is most often used in the AAVs. It provides an aide memoire to remind clinicians of the different manifestations that can occur in each of the organ systems. The absence of BVAS items is a valid definition of remission. The main emphasis is on recording features of active vasculitis requiring immunosuppression.
The Disease Extent Index (DEI) [18] developed for use in granulomatosis with polyangiitis (GPA) captures different domains of disease compared with BVAS; it is recommended as complementary to the BVAS in a variety of vasculitides, including ANCA vasculitis [18] and cryoglobulinaemic vasculitis [19] . Initial BVAS is predictive of future damage and higher levels of disease activity are associated with lung involvement at baseline [20] . BVAS is an effective, practical method for evaluating patients [21] .
The quantitative use of BVAS allows comparison between different disease states for individual patients or across groups of patients given different therapies. However, the range of BVAS values is different for different diseases due to the pattern of organ involvement. For example, in Takayasu's arteritis, the BVAS range will be relatively narrow because the areas of involvement are the cardiovascular system and general systemic system. In contrast, in GPA, almost any system can be involved, generating much higher scores. Therefore, we cannot use BVAS to compare activity between different types of vasculitis because this is biased by the organ involvement or the pattern of organ involvement for each form of vasculitis [11] .
Two clinical trials have used BVAS or BVAS/GPA as part of the entry criteria for eligibility for inclusion in clinical studies. A study of gusperimus in resistant GPA required a minimum score of four points using BVAS [22] for eligibility; the rituximab in ANCA vasculitis trial (RAVE) defined active disease as a minimum of 3 points using BVAS/GPA [23] . BVAS and BVAS/ GPA have been used as measurements of response or relapse in clinical trials [24] . Typically, remission is defined as an absence of BVAS items for a sustained period from 2 to 6 months. Relapse can be defined by a re-occurrence of BVAS items (either major or minor) [23, 24] . The term 'response' (defined as a 50% or greater reduction in initial BVAS score) has been used to categorize improvement in a study of gusperimus in resistant GPA, where the likelihood of remission was lower [22] . Table 1 lists the items used in the BVAS assessment.
Damage assessment
Patients with vasculitis have a chronic, relapsing course in most cases, with episodes of flare disease combined with chronic scarring (damage) as a result of the disease, its treatment and comorbidity resulting in increasing organ dysfunction. Damage worsens the patient's condition but does not respond to immunosuppression and is distinct from disease activity. Therefore, the patient with vasculitis should have documentation of their comorbidity and damage in addition to evaluating their disease activity. It is not uncommon for patients to have good control of their disease activity, but to develop significant damage which itself requires intervention. For example, if patients develop renal failure from vasculitis, their active disease may be well controlled following immunosuppression, but they might remain or become dialysis dependent. The renal failure is probably no longer due to disease activity but represents disease scarring.
The VDI was developed to separate disease activity from damage. It is a comprehensive list of items representing chronic damage and scarring occurring following diagnosis of vasculitis [13] . The VDI is a checklist whose items overlap with the BVAS checklist; but the philosophy behind scoring it is very different. The damage index accumulates over time and can only stay stable or get worst in individual patients. The rules regarding the damage index are different from those of disease activity scoring; damage is scored on the basis that it has lasted at least 3 months or occurred 3 months ago. Damage is non-attributable. In other words it is scored if present and occurring after the diagnosis of vasculitis is made, but is independent of cause. Damage may have occurred as a result of other inter-current unrelated events or illness; but if it appears on the damage list in a patient who has had a diagnosis of vasculitis, then it is scored. This is different from the BVAS which relies on discriminating what is due to active vasculitis from other events or damage.
The main benefit of using a damage index regularly is to allow clinicians to record the presence of comorbidity separately from recording the presence of disease activity, and therefore being able to separate these two aspects of the disease so that a management plan can be offered to the patients which takes account of not only disease activity but also the comorbidity and damage. For example, it would be necessary to manage the disease activity with steroids and immunosuppressive agents but at the same time it may be necessary to manage the patient's diabetes, hypertension or ischaemic heart disease with conventional strategies for these conditions.
The second important aspect of measuring damage is that it allows clinicians to record morbidity in the absence of disease activity, thereby preventing them from recording these events as disease activity and perhaps leading to overuse of immunosuppressive therapy. Once a patient has a diagnosis of vasculitis, it does not necessarily follow that all subsequent events are due to active vasculitis. Infections and chronic comorbidity are increasingly important aspects of the patient's condition which need recognition. The third benefit of the damage index is as a prognostic tool, as discussed below.
The damage index cannot cover all items that occur in the patient, and therefore there is an additional section in the damage of section 'other' to allow the clinician to describe other events that are defined as damage but do not appear on the main damage item list. The combined damage assessment (CDA) tool has been developed to improve the description of damage to provide more detail and to consider the possibility of reversibility of some damaged items. CDA has been tested in comparison to the original damage index but found to be too cumbersome for practical use and not to add any value to the existing damage index [25] . The items in the VDI are listed in Table 2 .
Q U A L I T Y O F L I F E A S S E S S M E N T
Assessment of functional outcome in vasculitis
Patients experience disease activity and damage, but this is independent of their ability to function. Performance of their activity in daily life can be significantly impaired directly by disease but different patients function at different levels for the same amount of disease activity or scarring. Measuring how the patients are able to manage everyday life despite their condition is important. The overall reduction in quality of life appears similar to that found in other chronic diseases [26] . Fatigue in AAV is common, affecting about 75% of patients and often related to sleep disorders and pain [27] . Fatigue, depression, damage (VDI) and being overweight are significant factors resulting in unemployment in around a quarter of patients with ANCA vasculitis who are of working age [28] . A small controlled study looking at functional magnetic resonance imaging brain imaging suggests that patterns of blood oxygen level use in the brain are different between fatigued and non-fatigued patients with GPA [29] .
Patient-reported outcome measures are increasingly used as ways of measuring the effectiveness of a clinical service or a treatment. Some measures are generic and can be applied across of a variety of conditions, such as Short-Form 36 (SF-36) and EuroQol 5D (EQ-5D). Both are generic instruments of quality of life and validated in different countries and across For new patients, all features of active vasculitis are recorded, regardless of the time frame. At follow-up, new or worse features are only recorded if occurring in the previous 4 weeks. Persistent disease represents ongoing low grade activity and is defined as lasting up to 3 months. During follow-up it is not unusual for patients to have a mixture of improving or resolving features plus new features arising. For example, in a patient with GPA, the initial presentation may be with a rash, nasal crusting and hearing loss which usually responds to methotrexate and steroid; but at follow-up, the patient may develop progression of disease with haematuria, proteinuria and impaired renal function. a variety of different conditions. SF-36 reflects poor functional outcome in patients with ANCA vasculitis [30] .
Following successful treatment of active vasculitis, functional outcome can remain significantly lower than population norms [31] . There is a correlation between functional outcome and damage [23] , but not between functional outcome and disease activity [30, 31] . SF-36 provides a more comprehensive overall view of the patient's function which can be compared across diseases. EQ-5D is a simpler tool to evaluate functional status and has been shown to improve in response to rituximab in cryoglobulinaemic vasculitis [32] . It is likely that the best measurement of functional outcome will be a combination of a disease-specific instrument plus a generic instrument.
There have been attempts to develop disease-specific instruments to evaluate functional outcome in AAV, but they are not in use at present. A measure developed from a physiciandesigned questionnaire has been validated for use in GPA [33] . A new initiative to develop specific functional assessment measures in ANCA vasculitis is underway and is entirely based on patient experience, and the results should be available within the next 12 months.
P R E D I C T I V E VA L U E O F A S S E S S M E N T TO O L S
Patients and doctors want to know the prognosis of having a diagnosis of vasculitis. In clinical trials it is useful to know whether a patient has a good or a bad prognosis to measure the effects of therapy to be able to stratify individuals with a worse prognosis to receive more aggressive therapy than those with a better prognosis. The Five Factor Score (FFS) [34] [35] [36] has been validated in patients with small and medium vessel vasculitis (originally for polyarteritis nodosa and eosinophilic granulomatosis with polyangiitis, but more recently also for granulomatosis with polyangiitis and microscopic polyangiitis), based on the extent of organ involvement.
The FFS includes items present at baseline which influence the risk of mortality. Any patient with at least one of the five factors has a much higher risk of dying than patients who have no risk factors. The original FFS included the following items: colon, renal impairment, proteinuria, gastrointestinal (GI) disease, cardiac involvement and central nervous system (CNS) involvement. It has been used in trials to stratify on the basis of disease severity: patients who either have at least one FFS or no factors have been randomized to either receive cyclophosphamide in addition to steroids, or steroids alone.
The current version of FFS [36] includes four positive factors: age (above 65), CNS involvement, cardiac involvement and renal involvement (which worsen the prognosis); and one negative factor: ENT involvement (which improves the prognosis).
BVAS also provides prognostic information and is effective in a number of studies in vasculitis: high BVAS at diagnosis predicts poor subsequent outcome in terms of mortality, but it also predicts responsiveness to therapy [37, 38] . However, poor outcome is also affected by age and baseline renal function [1] .
The damage index, VDI, is probably the most accurate predictor for outcome that we currently have. Patients with more than five items on the VDI scale by 6 months after diagnosis have a subsequent risk of death of 17:1 compared with patients with five or less items on the VDI. This is even higher when critical items are involved, such as those in the cardiovascular or neurological system [39] .
Understandably, patients who accumulate more damage rapidly are more likely to die. Patients with poor baseline renal function (creatinine >200 µmol/L) have a reduced risk of future flare, with a sub-hazard ratio of 0.39 (95% confidence interval: 0.22-0.69) [2] . Gene expression of the interleukin-7 receptor (IL-7R) pathway and T-cell receptor (TCR) signalling in memory T cells from patients with active or inactive vasculitis has been useful in predicting future relapse [40] , independent of the current state of activity. Table 2 . Disease damage assessment is based on the accumulation of nonhealing scars from disease, its treatment or comorbidity, irrespective of cause, occurring after the diagnosis of vasculitis is made and lasting at least 3 months or occurring at least 3 months ago in the case of episodic events such as myocardial infarction or stroke [7] 
T H E F U T U R E O F A S S E S S M E N T
The evaluation of disease activity and damage is different in children compared with adults because the range of clinical manifestations of disease activity can be similar but there are also differences [41] ; furthermore the consequences of having the diagnosis of vasculitis are different when comparing adults with children, in terms of damage [42] . There has been an initiative to develop paediatric-specific vasculitis assessment measures including the Paediatric Vasculitis Assessment Score (PVAS) [43] and Paediatric Vasculitis Damage Index (PVDI). The PVAS has been validated in a small number of children with vasculitis and is undergoing further validation in current studies. The PVDI, a modification of the adult VDI, has been developed but requires validation in children with vasculitis. The Japanese Vasculitis Assessment Score (JVAS) is a simple prognostic index based on creatinine, CRP, age and the presence or absence of lung involvement. It has been validated in Japanese patients with microscopic polyangiitis as a prognostic tool, but it does not provide the more comprehensive checklist in BVAS or VDI [44] .
Patients need careful evaluation of vasculitis, in order to stratify them to decide on the best therapy. Currently available clinical scores are validated and valuable for documenting disease status, response to therapy and for defining terms such as remission or relapse. We have some insight into prognosis based on simple clinical measurements within the first year of disease. Until more rigorous biomarkers become available that can predict outcome or describe these states more accurately, comprehensive clinical tools based on clinical checklists are strongly recommended both in clinical trials and increasingly in clinical practice.
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